Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - Provectus Pharmaceuticals, Inc. (PVCT-OCT: BB) |
|
|
We have solved the essential problem that other scientists and companies have not been able to solve; that is to make a cancer specific drug. We have found out how to make it simply, pragmatically and inexpensively; namely, to build it and make a very safe molecule. - Dr. H. Craig Dees, Ph.D. (PVCT) (Interview published April 12, 2007) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Provectus News Maxim Group Issues
Update Reflecting PH-10 Phase II Clinical Results in Psoriasis and
Atopic Dermatitis Maxim Group has issued a Company Update on Provectus to reflect the recently announced promising results from the two completed Phase II clinical studies of PH-10 for psoriasis and atopic dermatitis. A copy of the Company Update in PDF format is attached to this message. If you did not recieve the attachment, or are unable to view it, please call Porter, LeVay & Rose at +1 (212) 564-4700 or contact Peter Culpepper via e-mail at culpepper@pvct.com to request a copy.
|
|
